NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.17 +0.01 (+0.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.14▼$1.1850-Day Range$1.06▼$1.5052-Week Range$0.50▼$1.90Volume315,933 shsAverage Volume1.32 million shsMarket Capitalization$67.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get SELLAS Life Sciences Group alerts: Email Address SELLAS Life Sciences Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside156.4% Upside$3.00 Price TargetShort InterestBearish16.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector824th out of 936 stocksPharmaceutical Preparations Industry384th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.83% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 9.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 2.0 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.75) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About SELLAS Life Sciences Group Stock (NASDAQ:SLS)SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Read More SLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLS Stock News HeadlinesJuly 25 at 7:14 PM | yahoo.comSLS Core Stage ArrivesJuly 22, 2024 | msn.comConnect Life Sciences Strengthens Board with Two New AppointmentsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 18, 2024 | americanbankingnews.comSELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)July 16, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaJuly 8, 2024 | globenewswire.comSELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJune 24, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaJune 17, 2024 | globenewswire.comSELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 10, 2024 | globenewswire.comSELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AMLMay 22, 2024 | finance.yahoo.comCan SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?May 17, 2024 | markets.businessinsider.comStrong Buy Rating on SELLAS Life Sciences Amid Progress in AML Treatment PipelineMay 14, 2024 | msn.comSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024May 14, 2024 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | seekingalpha.comSLS SELLAS Life Sciences Group, Inc.May 3, 2024 | msn.comSamsung's Life Science Fund invests in Seattle's Latus BioMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)May 1, 2024 | msn.comSellas reports positive Phase 2 data from AML study, files for patentSee More Headlines Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+157.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-5,258.30% Return on Assets-249.95% Debt Debt-to-Equity RatioN/A Current Ratio1.49 Quick Ratio1.49 Sales & Book Value Annual Sales$1 million Price / Sales67.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.66Miscellaneous Outstanding Shares57,755,000Free Float56,831,000Market Cap$67.28 million OptionableNot Optionable Beta2.41 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Angelos M. Stergiou M.D. (Age 48)ScD h.c., Founder, President, CEO & Director Comp: $921.99kMr. John Thomas Burns CPA (Age 39)Senior VP & CFO Comp: $338.45kMs. Stacy E. YeungVP, Associate General Counsel & Head of ComplianceDr. Dragan Cicic M.D. (Age 61)MBA, Senior Vice President of Clinical Development Comp: $466.43kMr. Andrew ElnatanVP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & QualityKey CompetitorsEledon PharmaceuticalsNASDAQ:ELDNNeos TherapeuticsNASDAQ:NEOSCellectar BiosciencesNASDAQ:CLRBMillendo TherapeuticsNASDAQ:MLNDCorrevio PharmaNASDAQ:CORVView All CompetitorsInstitutional OwnershipVirtu Financial LLCSold 20,485 shares on 5/20/2024Ownership: 0.068%Anson Funds Management LPBought 4,832,368 shares on 5/14/2024Ownership: 8.366%View All Institutional Transactions SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.06 at the beginning of the year. Since then, SLS stock has increased by 10.4% and is now trading at $1.17. View the best growth stocks for 2024 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.21) earnings per share for the quarter. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.